Application of VIP/NTM-reactive natural antibodies in therapy of HIV disease.
In sera of HIV-infected individuals natural antibodies recognizing nonimmunogenic C-terminal domain of the second conserved region of HIV-1 gp120 and the vasoactive intestinal peptide (VIP) were identified. It has been demonstrated that these antibodies are significantly more prevalent in asymptomatic carriers than in AIDS patients and that their titer strongly correlates with disease progression. These findings point out the VIP/C2-reactive natural antibodies as an important agent for immunotherapy of HIV disease.
Veljkovic
Veljko
V
Center for Multidisciplinary Research, Institute of Nuclear Sciences VINCA, Belgrade, Yugoslavia. veljko01@hotmail.com
Metlas
Radmila
R
D000328:Adult; D018791:CD4 Lymphocyte Count; D005260:Female; D005500:Follow-Up Studies; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D014660:Vasoactive Intestinal Peptide / Q000276:immunology*
D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D014660:Vasoactive Intestinal Peptide